Abstract
In the evolutionary context, alterations in the basic DNA structure and fidelity of repair endow the genome with dynamism not only to survive but also to flourish. The genomic variation tools presented by evolution such as small tandem repeats (STRs), variable number of tandem repeats (VNTRs) and trinucleotide repeats (TNRs) are the most interesting. Cloning of several disease genes have identified the basic DNA structure instability attributed to nucleotide repeats in the form of changes in the tract length, threshold value, secondary structure formation, interruptions, mismatch repairs, the gene and its sequence involved as the basis for manifestation of a pathological phenotype, particularly several neurological disorders. The neurodegenerative disorders (NDDs) are chronic and progressive, characterized by selective and symmetric loss of neurons in motor, sensory and cognitive systems. The genetic anomalies that are responsible for these diseases are varied and complex. The observations on the disease age - of - onset with the length of expansion provided a strong indication that a novel toxic property of the altered protein or lack of expression of protein(s) is associated with the pathology. The conditions that ultimately lead to neuronal death, probably by apoptosis, involving oxidative stress, perturbed calcium homeostasis, mitochondrial dysfunction and activation of cysteine proteases called caspases include Huntingtons disease, Machado-Joseph disease and amylotropic lateral sclerosis among trinucleotide disorders and other NDDs like Alzheimers disease (AD) and Parkinsons disease (PD) seems to be shared. Presently, there are very few means to impede the disease progression, as there is loss of specific neuronal cell population in different disorders. The investigations on each aspect of these disorders will bring tremendous clinical benefits, offering better classification of the diseases and thus facilitating early diagnosis and genetic counseling. This review briefly summarizes research work directed towards understanding the pathophysiology of neurological disorders at the molecular level and highlights the trends in the current and future therapeutic approaches. Although the goal of delaying the onset of brain disorders may be within the grasp of modern medicine, there are several critical barriers to progress. Traditionally, in drug discovery, testing, and development, a combination of models, including in vivo, in vitro, transgenic, animal and microbial models is used. Advances in computer technology, in the form of “in silico” modeling systems, is there to complement currently available models and enable investigators to simulate alternative strategies to modulate neural function in a dynamic interactive mode and are expected to accelerate the drug discovery process. Understanding the complexities of the cellular pathology of the multistep, multifactorial diverse group of NDDs and associated paraphernalia of structural and functional alterations leading to proteinopathies would provide an opportunity for designing rational approaches for therapeutic regimen towards effective treatment. Successful discovery and development of therapeutic regimen will improve and reduce hospitalization and long-term care costs and suffering.
Keywords: Proteinopathies, Alzheimer, neurodegenerative
Current Genomics
Title: Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Volume: 5 Issue: 4
Author(s): L. K. Sengupta and S. Sengupta
Affiliation:
Keywords: Proteinopathies, Alzheimer, neurodegenerative
Abstract: In the evolutionary context, alterations in the basic DNA structure and fidelity of repair endow the genome with dynamism not only to survive but also to flourish. The genomic variation tools presented by evolution such as small tandem repeats (STRs), variable number of tandem repeats (VNTRs) and trinucleotide repeats (TNRs) are the most interesting. Cloning of several disease genes have identified the basic DNA structure instability attributed to nucleotide repeats in the form of changes in the tract length, threshold value, secondary structure formation, interruptions, mismatch repairs, the gene and its sequence involved as the basis for manifestation of a pathological phenotype, particularly several neurological disorders. The neurodegenerative disorders (NDDs) are chronic and progressive, characterized by selective and symmetric loss of neurons in motor, sensory and cognitive systems. The genetic anomalies that are responsible for these diseases are varied and complex. The observations on the disease age - of - onset with the length of expansion provided a strong indication that a novel toxic property of the altered protein or lack of expression of protein(s) is associated with the pathology. The conditions that ultimately lead to neuronal death, probably by apoptosis, involving oxidative stress, perturbed calcium homeostasis, mitochondrial dysfunction and activation of cysteine proteases called caspases include Huntingtons disease, Machado-Joseph disease and amylotropic lateral sclerosis among trinucleotide disorders and other NDDs like Alzheimers disease (AD) and Parkinsons disease (PD) seems to be shared. Presently, there are very few means to impede the disease progression, as there is loss of specific neuronal cell population in different disorders. The investigations on each aspect of these disorders will bring tremendous clinical benefits, offering better classification of the diseases and thus facilitating early diagnosis and genetic counseling. This review briefly summarizes research work directed towards understanding the pathophysiology of neurological disorders at the molecular level and highlights the trends in the current and future therapeutic approaches. Although the goal of delaying the onset of brain disorders may be within the grasp of modern medicine, there are several critical barriers to progress. Traditionally, in drug discovery, testing, and development, a combination of models, including in vivo, in vitro, transgenic, animal and microbial models is used. Advances in computer technology, in the form of “in silico” modeling systems, is there to complement currently available models and enable investigators to simulate alternative strategies to modulate neural function in a dynamic interactive mode and are expected to accelerate the drug discovery process. Understanding the complexities of the cellular pathology of the multistep, multifactorial diverse group of NDDs and associated paraphernalia of structural and functional alterations leading to proteinopathies would provide an opportunity for designing rational approaches for therapeutic regimen towards effective treatment. Successful discovery and development of therapeutic regimen will improve and reduce hospitalization and long-term care costs and suffering.
Export Options
About this article
Cite this article as:
Sengupta K. L. and Sengupta S., Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders, Current Genomics 2004; 5 (4) . https://dx.doi.org/10.2174/1389202043349282
DOI https://dx.doi.org/10.2174/1389202043349282 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adult Stem Cell Treatment for Central Nervous System Injury
Current Tissue Engineering (Discontinued) Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Tuning the Electronic Properties by Width and Length Modifications of Narrow- Diameter Carbon Nanotubes for Nanomedicine
Current Medicinal Chemistry Mitochondria as an Easy Target to Oxidative Stress Events in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Cellular Protective Effects of Rosmarinic Acid: From Bench to Bedside
Current Neurovascular Research Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders
Current Pharmaceutical Design Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Synaptic Plasticity in PTSD and associated Comorbidities: The Function and Mechanism for Diagnostics and Therapy
Current Pharmaceutical Design Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Role of Antioxidants in Redox Regulation of Diabetic Cardiovascular Complications
Current Pharmaceutical Biotechnology Is Nicotine Protective Against Parkinson´s Disease? An Experimental Analysis
CNS & Neurological Disorders - Drug Targets Computational Approaches to Screen Candidate Ligands with Anti- Parkinson’s Activity Using R Programming
Current Topics in Medicinal Chemistry Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Role of Flavonoids in Neurodegenerative Disorders with Special Emphasis on Tangeritin
CNS & Neurological Disorders - Drug Targets